36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Authors:

Abstract
Disclosures. Mauro:Abbvie, Janssen, Beigene, Astra Zeneca, Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speake